Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy



Status:Recruiting
Conditions:Neurology, Epilepsy
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:Any
Updated:1/31/2019
Start Date:February 20, 2017
End Date:November 9, 2020
Contact:Eisai Medical Information
Email:esi_medinfo@eisai.com
Phone:1-888-274-2378

Use our guide to learn which trials are right for you!

An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 24 Months (<2 Years) of Age With Epilepsy

The purpose of this study is to evaluate the pharmacokinetics (PK) of an oral suspension of
perampanel given as an adjunctive therapy and to generate preliminary safety and efficacy
data in pediatric participants, ranging from 1 month to less than 24 months of age, with
epilepsy.

This is a multicenter, open-label study comprised of pretreatment, treatment (core study),
and extension phases that is designed to evaluate the PK of an oral suspension of perampanel
(target dose of 12 milligrams per day [mg /day] for non-enzyme-inducing antiepileptic drug
[non-EIAED] or 16 mg/day for EIAED) when given as an adjunctive therapy in participants
ranging from 1 month to less than 24 months (<2 years) of age with epilepsy. The Pretreatment
Phase will last up to 2 weeks, during which participants will be assessed for their
eligibility to participate in the study. The Treatment Phase will consist of 3 periods:
Titration (12 to 16 weeks), Maintenance (4 weeks), and Follow-Up (4 weeks; only for those
participants who complete the Maintenance Period but do not continue into the Extension Phase
and those participants who discontinue study participation). The Extension Phase will consist
of 2 periods: Maintenance (32 to 36 weeks) and Follow-Up (4 weeks).

The maximum total duration of treatment for each participant will be 52 weeks, and the
maximum total duration of the study for each participant will be 58 weeks (52 weeks of
treatment + 2 weeks of pretreatment + 4 weeks of follow-up).

Inclusion Criteria:

- Male or female, from 1 to less than 24 months (<2 years) of age (and of at least 36
weeks gestational age) at the time of consent

- Have a minimum weight of 4 kilograms (kg) (8.8 pounds [lb])

- Have a diagnosis of epilepsy with any type of seizure according to the International
League Against Epilepsy's (ILAE) Classification of Epileptic Seizures (1981).
Diagnosis should have been established at least 2 weeks (≤6 months of age) or 4 weeks
(>6 months of age) before Visit 1, by clinical history and an electroencephalogram
(EEG) that is consistent with epilepsy; normal interictal EEGs will be allowed
provided that the participant meets the other diagnosis criterion (i.e., clinical
history)

- Have had brain imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
before Visit 1 that ruled out a progressive cause of epilepsy

- Have had 1 or more seizure(s) before Visit 1

- Currently being treated with a stable dose (i.e., unchanged for at least 5 half-lives)
of 1 to a maximum of 3 antiepileptic drugs (AEDs) (at least 6, but not more than 8,
participants will be taking 1 enzyme-inducing AED [EIAEDs] out of the maximum of 3
AEDs allowed. The remaining participants cannot be taking any EIAEDs).

- Have been on their current concomitant AED regime with a stable dose for at least 2
weeks (≤6 months of age) or 4 weeks (>6 months of age) before Visit 1

- Must have discontinued all restricted medications at least 2 weeks or 5 half-lives
(whichever is longer) before Visit 1

- If entering the Extension Phase, must have completed the last visit of the Maintenance
Period of the Core Study

Exclusion Criteria:

- Have a history of status epilepticus that required hospitalization during the 3 months
before Visit 1

- Have seizures due to treatable medical conditions, such as those arising due to
metabolic disturbances, toxic exposure, or an active infection

- Have epilepsy secondary to progressive central nervous system (CNS) disease or any
other progressive neurodegenerative disease, including tumors

- Have had epilepsy surgery within 1 year of Visit 1

- Are scheduled and/or confirmed to have epilepsy surgery within 6 months after Visit 1

- Used intermittent rescue benzodiazepines (i.e., 1 to 2 doses over a 24-hour period
considered one-time rescue) 2 or more times in the 2 weeks before Visit 1

- Prior use of felbamate

- Prior use of vigabatrin

- Are on ketogenic diet regimen that has not been stable for at least 4 weeks before
Visit 1

- Have used other drugs known to influence the CNS, where the dose has not been
stabilized for at least 2 weeks (≤6 months of age) or 4 weeks (>6 months of age)
before Visit 1

- Have any concomitant illnesses/co-morbidities that could severely affect the
participant's safety or study conduct

- Have evidence of clinically significant disease (e.g., cardiac, respiratory,
gastrointestinal, renal disease) that in the opinion of the investigator(s) could
affect the participant's safety or study conduct

- Have clinically significant laboratory abnormalities or any clinically acute or
chronic disease

- Have evidence of significant active hepatic disease. Stable elevation of liver
enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) due to
concomitant medication(s), will be allowed if they are less than 3 times the upper
limit of normal (ULN)

- Have clinical evidence of significant active hematological disease; white blood cell
(WBC) count ≤2500/ microliter (μL) (2.50 x 10^9/Liter [L]) or an absolute neutrophil
count ≤1000/μL (1.00 x 10^9/L)

- Have conditions that may interfere with their participation in the study and/or with
the PK of study drug

- Have participated in a study involving administration of an investigational drug or
device within 4 weeks before Visit 1, or within approximately 5 half-lives of the
previous investigational compound, whichever is longer

- Have previously participated in a clinical trial involving perampanel

- Have a clinically significant ECG abnormality, including prolonged corrected QT
interval (QTc) defined as >450 milliseconds (msec)

- Have had multiple drug allergies or a severe drug reaction to an AED(s), including
dermatological (e.g., Stevens-Johnson syndrome), hematological, or organ toxicity
reactions
We found this trial at
15
sites
?
mi
from
Tampa, FL
Click here to add this to my saved trials
1 Perkins Square
Akron, Ohio 44308
(330) 543-1000
Akron Children's Hospital From humble beginnings as a day nursery in 1890, Akron Children
?
mi
from
Akron, OH
Click here to add this to my saved trials
2401 Gillham Rd
Kansas City, Missouri 64108
(816) 234-3000
Children's Mercy Hospital Children's Mercy Hospitals and Clinics continues redefining pediatric medicine throughout the Midwest...
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
7485 Sandlake Commons Blvd.
Orlando, Florida 32835
?
mi
from
Orlando, FL
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
6811 Austin Center Boulevard
Austin, Texas 78731
?
mi
from
Austin, TX
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Brno,
Click here to add this to my saved trials
Gulf Breeze, Florida 32561
?
mi
from
Gulf Breeze, FL
Click here to add this to my saved trials
Lexington, Kentucky
859) 257-9000
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Loxahatchee Groves, Florida 33470
?
mi
from
Loxahatchee Groves, FL
Click here to add this to my saved trials
San Antonio, Texas 78258
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Urbana, Illinois 61801
?
mi
from
Urbana, IL
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials